Scienture Holdings Inc (SCNX)
Scienture Holdings, Inc. is a healthcare company focused on developing and commercializing pharmaceutical products for central nervous system and cardiovascular conditions in the United States. The company operates through two segments: Integra, which handles the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products, and Scienture, which is responsible for branded pharmaceutical research and development. Its pipeline includes SCN-102, an oral liquid losartan potassium formulation in phase 1 for hypertension, diabetic nephropathy, and stroke risk reduction in patients with hypertension and left ventricular hypertrophy, along with SCN-104, a multi-dose DHE injection pen. The company is also developing SCN-106, a thrombolytic agent, and SCN-107, a long-acting injectable non-opioid analgesic formulation. Scienture Holdings is based in Tampa, Florida.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SCNX
|
$0.50
|
22.7% Upside
|
Undervalued
|
$1.50
|
268.6% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-0.4x
|
0.2x
|
34.6x
|
16.902 M
|
13.004 M
|
0.1%
|
80.7%
|
-15.8
|
—
|
31.9%
|
